您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > BLU-5937
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
BLU-5937
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
BLU-5937图片
CAS NO:2417288-67-4
包装与价格:
包装价格(元)
5mg电议
10mg电议
50mg电议
100mg电议

产品介绍

BLU-5937 是一种有效的,选择性的,口服活性的 P2X3 同型三聚体受体拮抗剂,对人 P2X3,大鼠 P2X3 和豚鼠 P2X3 受体的 IC50 分别为 25 nM,92 nM 和 126 nM。BLU-5937 对人,大鼠和豚鼠 P2X2/3 异三聚体受体的活性较低。BLU-5937 具有很强的镇咳作用。

Cas No.2417288-67-4
Canonical SMILESO=C(OC)N1C[C@@H](CCC1)CC2=C(N=C3C=C(C=CN32)C)C4=C(C=C(C=C4F)C(NC)=O)F
分子式C24H26F2N4O3
分子量456.49
储存条件-20°C, protect from light
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

BLU-5937 is a potent, selective and orally active P2X3 homotrimeric receptor antagonist with IC50s of 25?nM, 92?nM and 126?nM for human P2X3, rat P2X3 and guinea pig P2X3 receptors, respectively. BLU-5937 is less active against human, rat and guinea pig P2X2/3 heterotrimeric receptors. BLU-5937 has strong anti-tussive effect[1].

BLU-5937 (500?nM) is able to block αβ-meATP-induced sensitization and firing activity of isolated primary nociceptors in rat dorsal root ganglions (DRGs), through P2X3 homotrimeric receptor antagonism. The sensitizing effect of αβ-meATP and the inhibition of BLU-5937 are reversible after washout[1].

BLU-5937 (0.3-0mg/kg, oral administration; male Dunkin Hartley guinea pigs) treatment significantly reduces the histamine-induced enhancement in the number of citric acid-induced coughs in a dose-dependent fashion in a guinea pig cough model[1].BLU-5937 (3 and 30mg/kg, oral) is also shown to reduce significantly and dose-dependently the ATP-induced enhancement of citric acid-induced coughs in the guinea pig[1]. Animal Model: Male Dunkin Hartley guinea pigs[1]

[1]. Garceau D, et al. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. Pulm Pharmacol Ther. 2019 Jun;56:56-62.